The effect of inhaled prostaglandin (PG) F2, on the response to the inhaled tussive agent capsaicin was investigated in normal subjects. Seven subjects inhaled three breaths of four doses of capsaicin (0 3, 0-6, 12, and 2-4 nmol) before and immediately after inhaling PGF2. 
immediately after inhaling PGF2.
(0-1 pmol) or placebo (0-15M NaCl) on separate days. The numbers of capsaicin induced coughs were greater after PGF2, (mean 42-3 coughs) than after 015M sodium chloride (30-1). Visual analogue scores (0-10 on a 10 cm continuous scale) showed that capsaicin was more irritant after PGF2. than after saline. Total respiratory resistance (Rrs), measured by the forced oscillation technique, was unaltered throughout the study. A double blind, placebo controlled study of the effects of inhaled salbutamol (200 pg, 0-6 umol) and ipratropium bromide (40 pg, 0-1 pmol) on cough induced by capsaicin (2) (3) (4) nmol) and by PGF2.
(0X1 pmol) and on PGF2, augmented, capsaicin induced coughing was performed in seven subjects. Neither drug had any effect on capsaicin induced coughing. Salbutamol reduced coughing due to PGF2, (mean 7-7 coughs after salbutamol, 9-3 after placebo) but ipratropium bromide did not (mean [6] [7] [8] [9] coughs after ipratropium bromide, after placebo). Salbutamol also inhibited the augmentation of the capsaicin induced cough that followed inhalation of PGF2. (mean augmentation 1-9 coughs after salbutamol, 4-1 after placebo), whereas ipratropium bromide did not (augmentation 1P7 coughs after ipratropium bromide, 2-7 after placebo).
No changes in Rrs were seen after PGF2. or either drug. Thus salbutamol reduces PGF2. induced cough and the augmentation of capsaicin induced cough that follows PGF2.
Cough frequently accompanies disorders of the airways such as asthma, chronic bronchitis, and upper respiratory viral infections.' The precise abnormality in the cough response is not known, but presumably there is an increased sensitivity of laryngeal and airway cough receptors to cough provoking stimuli. For example, a viral upper respiratory infection in normal subjects leads to a reduction in the threshold dose of a tussive agent such as citric acid that produces coughing.2 Inflammatory mediators released within the airways may increase the sensitivity of cough receptors. One group of mediators, the prostaglandins, has recently been implicated as sulindac, a cyclooxygenase inhibitor, inhibits the cough induced by the angiotensin converting enzyme inhibitor captopril. 3 To explore the role of inflammatory mediators in cough sensitisation further, we determined whether prostaglandin (PG) F20, a cyclooxygenase product that activates airway sensory nerves, could enhance the cough response in normal subjects. We used inhaled capsaicin, the active ingredient of red pepper, as the tussive agent. Capsaicin stimulates airway sensory nerves, such as non-myelinated C fibres, to induce cough,4 an effect that is inhibited by the local anaesthetic agent lignocaine.5 Because cough is a feature of asthma, and because salbutamol, a beta adrenergic agonist, and ipratropium bromide, an anticholinergic agent, are used to treat asthma, we investigated the effects of these agents to see whether they modified any increase in capsaicin induced cough produced by PGF22.
Methods

SUBJECTS
Eleven healthy, non-smoking subjects (mean age 29, range 19-37 years; three female) with no previous history of lung or heart disease gave informed consent for the study, which was approved by the National Heart and Lung Hospital's ethics committee. Subjects were naive and had not previously taken part in studies on cough. They were told the general nature of the study but not its exact purpose. Seven subjects took part in each study, three subjects taking part in both. All subjects had been free of upper respiratory tract infections for at least four weeks and had no spontaneous coughing. None was taking any medication, except for the contraceptive pill.
COUGH CHALLENGE PROCEDURES
Capsaicin (Sigma Chemical Company, Poole) was dissolved in absolute alcohol to make a stock solution of 3 6 x 10-3 mol/l, which was stored at -20°C. This solution was diluted with 0-15M sodium chloride solution to make solutions of 45, 90, 180, and 360 pmol/l for inhalation for study 1. Subjects inhaled a single breath of each concentration of capsaicin in random order every minute and the challenge was repeated three times, so that 12 single challenges with capsaicin were performed. Each of the three runs was performed in the same order. Aerosols were delivered from a jet nebuliser attached to a breath actuated dosimeter (MEFAR, Brescia, Italy), which was set to trigger for 1-0 second at a pressure of 1-5 kg/cm2. The output of the nebuliser was 7-7 pl a breath; this produces particles with a mass mean diameter of 3-5 pm. Each breath was taken over five seconds, the subject inhaling from functional residual capacity to total lung capacity. The number of resulting coughs was counted by an independent observer. A visual analogue score was obtained after each inhalation, subjects being asked to evaluate the perceived intensity of the burning retrosternal sensation on a 10 cm straight line, taking 0 as indicating no detectable sensation and 10 the worst imaginable intensity. For study 2 only the highest concentration of capsiacin was used (360 pmol/1), and the capsaicin cough challenge was shortened to consist of four consecutive inhalations at one minute intervals.
PGF2, (Upjohn, Crawley) was nebulised at a concentration of 5 mg/ml (14-9 mmol/l) from the nebuliser-dosimeter system that was used for the capsaicin challenges. Salbutamol (Allen and Hanbury, Greenford) and ipratropium bromide (Boehringer Inngelheim, Bracknell) were delivered from metered dose inhalers.
MEASUREMENT OF RESPIRATORY RESISTANCE (RRs)
Total respiratory resistance was measured by the forced oscillation technique with an Oscillaire (Jones Instruments Company, Chicago) according to the method of Landser et al. 6 The seated subject was asked to breathe quietly on a mouthpiece connected to a screen pneumotachograph while supporting his cheeks with the palms ofhis hands. Oscillations at regular frequencies were generated by a loudspeaker and superimposed during tidal breathing. Two identical differential pressure transducers (Validyne PM5) were used to measure mouth pressure and flow across the pneumotachograph. A Fourier analysis of the pressure and flow signals at the mouth yielded mean Rrs values measured over 16 second periods. The superimposed signal consisted of a frequency spectrum of 4-52 Hz in steps of 2 Hz. As Rrs measured at 6 Hz appeared to be the most sensitive for recording change in airway calibre in normal subjects, only Rrs measured at this frequency is reported. For each measurement of Rrs we used the mean of three consecutive measurements obtained over 4-5 minutes.
PROTOCOL Study 1
We determined the effect of PGF2t, (one breath of 5 mg/ml) on capsaicin induced cough in a randomised, double blind, placebo controlled study. Subjects attended on two days, respiratory resistance (Rrs) being measured by the forced oscillation technique on each day, followed by a capsaicin cough challenge. One minute later subjects inhaled one breath of nebulised PGF2,, (5 mg/ml in nebuliser) or 0-15M sodium chloride solution (placebo), followed one minute later by a repeat capsaicin cough challenge. Rrs was measured after the final challenge.
Study 2
We next determined the effect of inhaled salbutamol and ipratropium bromide respectively on the increase in capsaicin induced cough produced by PGF2,, in two randomised, double blind, and placebo controlled studies that were otherwise identical. Each study consisted of two visits at which Rrs was measured, followed by a capsaicin challenge. Rrs day (fig 2) . This was more prolonged and qualitatively different from that caused by capsaicin. The PGF22 following salbutamol compared with placebo (7.7 and 9-3 respectively; p < 0-05). PGF2, potentiated capsaicin induced cough, the mean number ofcoughs increasing from 3 9 to 8-0 (p < 0-01) on the placebo day. Salbutamol caused a partial inhibition of this increase (p < 0-05)- figure 3 . The mean increase in coughs after PGF2, was 2 18 (95% confidence interval 0 26 to 4-1) more on the placebo day than on the salbutamol day. There was no significant change in Rrs after PGF20, salbutamol, or capsaicin (table) .
Ipratropium bromide Ipratropium bromide did not inhibit cough induced by capsaicin or PGF22; it caused some decrease in the PGF2, induced augmentation of capsaicin induced cough, but this was not significant (fig 3) . The augmentation of cough on the placebo day was 0 75 (95°,. confidence interval -0 23 to 1 25) coughs more than on the ipratropium day. There was no significant change in Rrs after PGF22, ipratropium, or capsaicin (table) . The PGF2, augmentation of capsaicin induced coughing was less on the salbutamol day than on the ipratropium day by 1 43 (950o confidence interval 012 to 227).
On the basis of changes in Rrs observed on the placebo days the study had an 800o power to detect a change in Rrs of 0 5 cm H20.l--IS1 at the 5 0 0 level of significance.
Discussion
We have shown that PGF2, augments the number of coughs induced by capsaicin in normal subjects and the subjective irritation that accompanies capsaicin inhalation. This increase in cough and irritation was not accompanied by detectable bronchoconstriction as measured by the forced oscillation technique. Salbutamol 
